Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Research & Development (2016 - 2025)

Jaguar Health (JAGX) has disclosed Research & Development for 11 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 9.52% to $3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.2 million, a 1.84% decrease, with the full-year FY2024 number at $16.5 million, down 11.05% from a year prior.
  • Research & Development was $3.7 million for Q3 2025 at Jaguar Health, up from $3.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.1 million in Q3 2023 to a low of $2.4 million in Q1 2021.
  • A 5-year average of $4.1 million and a median of $4.0 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 187.92% in 2021, then tumbled 36.67% in 2022.
  • Jaguar Health's Research & Development stood at $5.5 million in 2021, then dropped by 21.36% to $4.3 million in 2022, then fell by 19.67% to $3.5 million in 2023, then surged by 30.93% to $4.5 million in 2024, then dropped by 19.32% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Research & Development are $3.7 million (Q3 2025), $3.3 million (Q2 2025), and $3.7 million (Q1 2025).